Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: berblady who wrote (40)	1/5/2001 3:11:11 PM
From: Lighthouse	Respond to of 222

Thanks for the response. Indeed Coulter was Bexxar and thereby much easier to fathom. Bexxar is now one piece of Corixa (Latin for lots of moving parts?) 8-) Reading the CLTR/CRXA merger proposal did not give me warm fuzzies regarding Coulter management either. In the histroy of the deal section (page 64) Bigham went to Corixa on May 15, 2000, "to discuss Corixa's interest in a potential product collaboration with Coulter" My take is Bigham shopped this company/deal to Corixa. Lots of reasons to do this, but it is something you would not do if you were supremely confident. Perhaps he feared filing after Zevalin? Idec did a very good job and Corixa did a very good job. Coulter did not. Anyway Zevalin looks like it has more toxicity issues than Coulter and it will come second. But you know the old saying of pioneers? They are the ones with arrows in the chest. Cheers, P.S. Good to see you over here at SI - Have read your posts over at Yahoo for awhile.